Drug Interaction Report

Coadministration with niraparib may decrease the plasma concentrations of drugs that are substrates of the CYP450 1A2 isoenzyme. At high concentrations, niraparib is able to weakly induce CYP450 1A2. If niraparib is used in combination with substrates of CYP450 1A2, particularly those with a narrow therapeutic range (e.g., clozapine, theophylline, ropinirole), then monitoring for signs and symptoms of reduced exposure to the CYP450 1A2 substrate should be considered.

GENERALLY AVOID: Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

MANAGEMENT: Concomitant use of opioid analgesics with ethanol should be avoided.